Blog

• Hits and Misses by DANIEL S. LEVINE
  An analysis of pharma deals shows certain types are better predictors of success than others.
• Dishonor Roll by ERIC WAHLGREN
  U.S. health system's grade knocked down to a D.
• Whether The Couric Effect Is Real, It's Not Enough by DANIEL S. LEVINE
  CDC says despite improvements colorectal cancer screening rate remain too low.

Business

• Tall Order by JOEL MCCORMICK
  Can Singapore buy its way to the top of the biotech world with no background in entrepreneurship or science?
• Waking up from the Summer Slumber
  M&A activity sparks a summer rally in biotech.
• Genentech Rebuffs Roche
  A discussion from KQED-FM's Forum

Health

• Sleeping Giants
  The growing use of soporifics comes as healthcare professionals warn of the dangers from lack of sleep.
• Wait for Me by BRUCE GOLDMAN
  Consumers are embracing tests that aim to reveal genetic risk factors for disease. Problem is, the medical community doesn't seem ready to deal with all the data begging for interpretation.
• Borders without Doctors by ERIC WAHLGREN
  Efforts intensify to address health worker migration's toll on sub-Saharan Africa.

Law

• Billion Dollar Copycats
  Generic drugmakers tout billions in savings that could be realized with the introduction of biogenerics.
• Thinking Small     by LORI ANDREWS AND JULIE BURGER
  U.S. patent officials and other regulators must get up to speed on the intricacies of tiny particles to avoid hindering the growth of nanotechnology.
• Untethering Innovation     by BRADFORD PLUMER
  One year before a new president takes office, Congress lies low, but bills on patents, biologics, genetics, and a host of other issues could still affect R&D.

Magazine

• The Journal Of Life Sciences
  August/September 2008
• The Journal of Life Sciences
  June/July 2008 edition

Policy

• An Ounce Of Prevention by DANIEL S. LEVINE
  Biomedical research costs money, but it promises to fix the healthcare mess, save billions in the long run, and cure people even before they get sick.
• Public or Private? by PETER J. PITTS
  Commercial confidential information need to be protected to ensure innovation.
• Going Medieval on Cancer Patients by PETER J. PITTS
  Despite clinical evidence that a group of new cancer drugs help, NICE has decided they cost too much to use.

Science

• Why Darwin May Be Wrong by SANDYA VISWANATHAN
  Stanford's Joan Roughgarden takes issue with Darwinian theory of sexual selection, but she's no creationist. The evolutionary biologist believes it's time to look at sex in a new way.
• DNA Inside by LORI ANDREWS
  Bio-based computers may help scientists overcome the limitations of silicon-powered machines, leading to new nano-scale products as well as smart drugs that adjust to the environment inside the body.
• English, Gym, Algebra...Biotech by KIRK BROWN
  I've tried to inspire a new generation of scientists through an unusual curriculum and partnerships with industry.

Society

• The Gene Poll by ERIC WAHLGREN
  Researchers say heritability plays a role in voter turnout.
• Tangled Up In Blue
  Pharmaceutical industry breaks from its historical favoring of Republicans over Democrats on political spending.
• Love Stinks by JULIE CHAO
  Research finding that body odor influences attraction inspires a new dating site.

TJOLS-TV

• Oddities and Wonders
  A news round-up of the bizarre from the world of the life sciences
• TJOLS-TV
  The life sciences in the news
• What's So Funny About Cancer
  Mike Schneider interviews comedian Robert Schimmel on his fight with non-Hodgkin's lymphoma.